Major depressive disorder and response to citalopram treatment in women attending menopause clinic

Nóra Belso, Kitty Kiss, Zoltán Rihmer, Nándor Tüzko, Sándor János Tóth, Ferenc Paulin

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: The authors investigated the prevalence of depressive disorders and response to citalopram among perimenopausal women visiting menopause clinics. METHOD: One hundred and eighty-five consecutive outpatients were screened using the short Beck Depression Inventory A psychiatrist investigated persons who showed medium or severe Beck depression. In the case of DSM-IV major depressive episode, a 6-week open trial with citalopram (20-40 mg daily) was started. The 17-item Hamilton Depression Rating Scale (HDRS) measured the severity of depression at baseline and at weeks 3 and 6. The primary outcome measure was the rate of responders at weeks 3 and 6 (more than 50% drop in the total HDRS score at weeks 3 and 6 compared to baseline). RESULTS: Of the 185 consecutive outpatients screened, 48 (26%) have experienced medium or severe Beck depression, and 37 of them (20%) had DSM-IV major depression. Citalopram was started in 30 patients (daily doses ranged from 20 to 40 mg) and 21 (70%) finished the trial. The rate of responders at week 3 was 7/22 (32%) and at week 6 was 13/21 (62%). CONCLUSIONS: Depressive disorders are common among perimenopausal women visiting menopause clinics, and the majority of those with depression respond well to citalopram. Interdisciplinary cooperation is the key point of the detection and follow up of these patients.

Original languageEnglish
Pages (from-to)269-272
Number of pages4
JournalInternational Journal of Psychiatry in Clinical Practice
Volume7
Issue number4
DOIs
Publication statusPublished - Dec 1 2003

Keywords

  • Citalopram
  • Major depression
  • Menopause clinic
  • Perimenopause
  • SSRI treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Major depressive disorder and response to citalopram treatment in women attending menopause clinic'. Together they form a unique fingerprint.

  • Cite this